NEW YORK, April 06, 2018 -- According to a new research report titled “Oral Mucositis Therapeutics Pipeline Analysis, 2017” published by P&S Market Research, Oral Mucositis currently exhibits a pipeline with 18 drug candidates.
Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis/report-sample
The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Oral mucositis is the most common complication of chemotherapy in cancer patients. It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa.
Oragenics, Inc. is using ActoBiotics technology platform for the development of their drug candidates for the treatment of oral mucositis. The technology platform produces a new class of orally delivered biopharmaceuticals. Through ActoBiotics technology platform, food-grade microbes are engineered to generate biologically contained ActoBiotics therapeutics for in situ expression and secretion of novel proteins and peptides including cytokines, enzymes, hormones and monoclonal antibodies within the body.
Browse Full Report with detailed TOC on “Oral Mucositis Therapeutics Pipeline Analysis” at: https://www.psmarketresearch.com/market-analysis/oral-mucositis-therapeutics-pipeline-analysis
The research also found that various companies received designations from the USFDA for the development of the drugs in the oral mucositis therapeutics pipeline. In November 2016, USFDA granted Fast Track designation to AG013 for the treatment of oral mucositis.
Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.
More Reports Published by P&S Market Research
HSV Infections Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis
COPD Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook


Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Samsung Electronics Shares Jump on HBM4 Mass Production Report
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 



